Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Vivo Ventures Closes $375 Million US-China Life Science Fund

publication date: Jan 3, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Vivo Ventures, a California healthcare investment firm that invests in both US and China life science companies, closed its seventh fund, Vivo Ventures VII, at $375 million. In the US, the fund will target US companies in the later stage of development. Its China investments will seek enterprises that are producing revenues. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors